Pacira BioSciences (PCRX) Earnings Date, Estimates & Call Transcripts $25.38 -0.47 (-1.80%) As of 03:55 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Pacira BioSciences Earnings Summary Pacira BioSciences announced Q2 2025 earnings on August 5, 2025, reporting an EPS of $0.74, which beat analysts' consensus estimates of $0.73 by $0.01. Quarterly revenue rose 1.7% year-over-year to $181.10 million, below analyst estimates of $183.11 million. With a trailing EPS of -$2.78, Pacira BioSciences' earnings are expected to grow 6.64% next year, from $2.41 to $2.57 per share. Upcoming Q3 Earnings DateNov. 5After Market ClosesEstimatedConsensus EPS (Aug. 5) $0.73 Actual EPS (Aug. 5) $0.74 Beat By $0.01 Actual Revenue (Aug. 5) $181.10MQ2 2025 Earnings ResourcesQ2 2025 Earnings ReportConference Call Transcript & Audio Press Release (8-K) Quarterly Report (10-Q) Slide DeckPCRX Upcoming EarningsPacira BioSciences' next earnings date is estimated for Wednesday, November 5, 2025, based on past reporting schedules. Slide DeckFull Screen Slide DeckPowered by Get Pacira BioSciences Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pacira BioSciences and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataPCRX Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.PCRX Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Pacira BioSciences Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateRevenue EstimateCompany Revenue GuidanceQ1 20251$0.63$0.63$0.63Q2 20251$0.68$0.68$0.68Q3 20251$0.44$0.44$0.44Q4 20251$0.68$0.68$0.68 FY 2025 4 $2.43 $2.43 $2.43 Q1 20261$0.65$0.65$0.65Q2 20261$0.69$0.69$0.69Q3 20261$0.67$0.67$0.67Q4 20261$0.65$0.65$0.65 FY 2026 4 $2.66 $2.66 $2.66 Q1 20271$0.59$0.59$0.59Q2 20271$0.61$0.61$0.61 Pacira BioSciences Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 11/5/2025(Estimated)--------8/5/2025Q2 2025$0.73$0.74+$0.01-$0.11$183.11M$181.10M7/30/2024Q2 2024$0.53$0.64+$0.11$0.89$173.31M$178.02M5/7/2024Q1 2024$0.46$0.42 -$0.04$0.65$165.43M$167.12M2/29/2024Q4 2023$0.71$0.71-$0.92$180.60M$181.24M11/2/2023Q3 2023$0.65$0.52 -$0.13$0.81$172.83M$163.93M Pacira BioSciences Earnings - Frequently Asked Questions When is Pacira BioSciences' earnings date? Pacira BioSciences has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, November 5th, 2025 based off last year's report dates. Learn more on PCRX's earnings history. What guidance has Pacira BioSciences issued on next quarter's earnings? Pacira BioSciences updated its FY 2025 earnings guidance on Tuesday, August, 5th. The company issued revenue guidance of $730.0 million-$750.0 million, compared to the consensus revenue estimate of $739.1 million. Did Pacira BioSciences beat their earnings estimates last quarter? In the previous quarter, Pacira BioSciences (NASDAQ:PCRX) reported $0.74 earnings per share (EPS) to beat the analysts' consensus estimate of $0.73 by $0.01. Learn more on analysts' earnings estimate vs. PCRX's actual earnings. How can I listen to Pacira BioSciences' earnings conference call? The conference call for Pacira BioSciences' latest earnings report can be listened to online. Listen to Conference Call How can I read Pacira BioSciences' conference call transcript? The conference call transcript for Pacira BioSciences' latest earnings report can be read online. Read Transcript How much revenue does Pacira BioSciences generate each year? Pacira BioSciences (NASDAQ:PCRX) has a recorded annual revenue of $705.85 million. How much profit does Pacira BioSciences generate each year? Pacira BioSciences (NASDAQ:PCRX) has a recorded net income of -$99.56 million. PCRX has generated -$2.78 earnings per share over the last four quarters. What is Pacira BioSciences' EPS forecast for next year? Pacira BioSciences' earnings are expected to grow from $2.41 per share to $2.57 per share in the next year, which is a 6.64% increase. More Earnings Resources from MarketBeat Related Companies Perrigo Earnings Supernus Pharmaceuticals Earnings Nektar Therapeutics Earnings Omeros Earnings Assembly Biosciences Earnings Cumberland Pharmaceuticals Earnings Eli Lilly and Company Earnings Johnson & Johnson Earnings AbbVie Earnings Merck & Co., Inc. Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles After Earnings Miss, Walmart Is Still a Top Consumer Staples PlayRoyal Caribbean Earnings Beat Fuels Strong 2025 OutlookDLocal Stock Soars 43% After Earnings Beat and Raised GuidanceGreen Dot's 30% Rally: Turnaround Takes Off on Explosive EarningsElbit Systems Jumps on Record Earnings and a $1.6B ContractBrinker Serves Up Earnings Beat, Sidesteps Cost PressuresWhy BigBear.ai Stock's Dip on Earnings Can Be an Opportunity This page (NASDAQ:PCRX) was last updated on 8/25/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pacira BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pacira BioSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access